Literature DB >> 25968091

The emerging role of inhibitor of growth 4 as a tumor suppressor in multiple human cancers.

Shiyun Cui1, Yanping Gao, Kai Zhang, Jing Chen, Rui Wang, Longbang Chen.   

Abstract

Inhibitor of growth 4 (ING4), a member of the conserved ING family, has been identified as an important tumor suppressor since it plays a critical role in the regulation of chromatin modification, cell proliferation, angiogenesis and cell migration. Some observations suggest that ING4 acts as a key regulator of tumorigenesis through modifying gene transcription in part by regulating the transcription factors p53 and NF-kappaB (NF-κB). However, these models have yet to be substantiated by further investigations. Numerous reports describe the reduced expression of ING4 in cancers, and the responsible mechanisms are involved in gene deletion, mutation, transcriptional and post-transcriptional dysregulation. This review aims to summarize the recent published literature that investigates the role of ING4 in regulating tumorigenesis and progression, and explore its potential for cancer treatment.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25968091     DOI: 10.1159/000430108

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  10 in total

1.  Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).

Authors:  Heng-Jia Liu; Hilaire C Lam; Christian V Baglini; Julie Nijmeh; Alischer A Cottrill; Stephen Y Chan; Elizabeth P Henske
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

2.  Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells.

Authors:  Madeline M Keenen; Suwon Kim
Journal:  Breast Cancer (Dove Med Press)       Date:  2016-11-17

3.  ING4 suppresses tumor angiogenesis and functions as a prognostic marker in human colorectal cancer.

Authors:  Yansu Chen; Yefei Huang; Pingfu Hou; Zhe Zhang; Yafei Zhang; Weimin Wang; Guixiang Sun; Lichun Xu; Jianwei Zhou; Jin Bai; Junnian Zheng
Journal:  Oncotarget       Date:  2016-11-29

4.  Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma.

Authors:  A Galal El-Shemi; A Mohammed Ashshi; E Oh; B-K Jung; M Basalamah; A Alsaegh; C-O Yun
Journal:  Gene Ther       Date:  2017-09-19       Impact factor: 5.250

5.  Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus.

Authors:  Jiamin Peng; Shibing Wang; Weimin Fan; Shuangshuang Li; Yi Wu; Xiaozhou Mou; Jianchao Wang; Xiangmin Tong
Journal:  Onco Targets Ther       Date:  2018-10-15       Impact factor: 4.345

6.  ING4 suppresses hepatocellular carcinoma via a NF-κB/miR-155/FOXO3a signaling axis.

Authors:  Fuliang Qian; Qingqing Hu; Yali Tian; Jie Wu; Dapeng Li; Min Tao; Lei Qin; Bairong Shen; Yufeng Xie
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

7.  miR-650 promotes non-small cell lung cancer cell proliferation and invasion by targeting ING4 through Wnt-1/β-catenin pathway.

Authors:  Xiangqin Tang; Yanjun Ding; Xiaoqing Wang; Xiuzhen Wang; Lin Zhao; Hongmei Bi
Journal:  Oncol Lett       Date:  2019-09-04       Impact factor: 2.967

8.  ING4 Promotes Stemness Enrichment of Human Renal Cell Carcinoma Cells Through Inhibiting DUSP4 Expression to Activate the p38 MAPK/type I IFN-Stimulated Gene Signaling Pathway.

Authors:  Yu Tang; Xinyue Yang; Qing Wang; Haoyu Huang; Qinzhi Wang; Min Jiang; Chunluan Yuan; Yefei Huang; Yansu Chen
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988

9.  An in silico study of how histone tail conformation affects the binding affinity of ING family proteins.

Authors:  Nadir Gül; Ahmet Yıldız
Journal:  PeerJ       Date:  2022-09-30       Impact factor: 3.061

Review 10.  Functions and underlying mechanisms of miR-650 in human cancers.

Authors:  Yuanshuai Su; Qiuxian Zheng; Lingxiao Zhu; Xinyu Gu; Juan Lu; Lanjuan Li
Journal:  Cancer Cell Int       Date:  2022-03-24       Impact factor: 5.722

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.